论文部分内容阅读
Objective:To investigate the shared mechanisms of scutellarin in angina pectoris(AP)and ischemic stroke(IS)treatment.Methods:A network pharmacology approach was used to detect the potential mechanisms of scutellarin in AP and IS treatment by target prediction,protein-protein interaction(PPI)data collection,network construction,network analysis,and enrichment analysis.Furthermore,molecular docking simulation was employed to analyze the interaction between scutellarin and core targets.Results:Two networks were established,including a disease-target network and a PPI network of scutellarin targets against AP and IS.Network analysis showed that 14 targets,namely,AKT1,VEGFA,JUN,ALB,MTOR,ESR1,MAPK8,HSP90AA1,NOS3,SERPINE1,FGA,F2,FOX03,and STAT1,might be the therapeutic targets of scutellarin in AP and IS.Among them,NOS3 and F2 were recognized as the core targets.Additionally,molecular docking simulation confirmed that scutellarin exhibited a relatively high potential for binding to the active sites of NOS3 and F2.Furthermore,enrichment analysis indicated that scutellarin might exert a therapeutic role in both AP and IS by regulating several important pathways,such as coagulation cascades,mitogen-activated protein kinase(MAPK)signaling pathway,phosphatidylinositol 3 kinase(PI3K)/protein kinase B(Akt)/mammalian target of rapamycin(mTOR)signaling pathway,Toll-like receptor signaling pathway,hypoxia inducible factor-1(HIF-1)signaling pathway,forkhead box O(FoxO)signaling pathway,tumor necrosis factor(TNF)signaling pathway,adipocytokine signaling pathway,insulin signaling pathway,insulin resistance,and estrogen signaling pathway.Conclusions:The shared underlying mechanisms of scutellarin on AP and IS treatment might be strongly associated with its vasorelaxant,anticoagulant,anti-inflammatory,and antioxidative effects as well as its effect on improving lipid metabolism.